PRME:NSD-Prime Medicine, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.42

Change

-0.12 (-4.72)%

Market Cap

N/A

Volume

0.81M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-4.60 (-0.96%)

USD 118.90B
REGN Regeneron Pharmaceuticals Inc

-4.16 (-0.59%)

USD 73.95B
ARGX argenx NV ADR

+1.68 (+0.27%)

USD 40.41B
ALNY Alnylam Pharmaceuticals Inc

-6.76 (-2.77%)

USD 34.99B
ONC BeiGene, Ltd.

+19.38 (+7.48%)

USD 25.62B
RPRX Royalty Pharma Plc

-0.01 (-0.03%)

USD 18.65B
SMMT Summit Therapeutics PLC

+0.19 (+1.04%)

USD 17.01B
UTHR United Therapeutics Corporatio..

+4.73 (+1.48%)

USD 15.68B
INCY Incyte Corporation

-1.12 (-1.51%)

USD 14.29B
INSM Insmed Inc

+0.95 (+1.22%)

USD 13.70B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.12% 42% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.12% 42% F 24% F
Trailing 12 Months  
Capital Gain -71.96% 26% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -71.96% 26% F 10% F
Trailing 5 Years  
Capital Gain -88.04% 38% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.04% 38% F 12% F
Average Annual (5 Year Horizon)  
Capital Gain -25.66% 16% F 9% A-
Dividend Return -25.66% 16% F 9% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.46% 91% A- 68% D+
Risk Adjusted Return -96.99% 7% C- 4% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector